Advances in pathogenesis and management of sepsis

Current Opinion in Infectious Diseases

Volumn 20, Issue 4, 2007, Pages 345-352

  Cinel, Ismail ^a   Dellinger, R Phillip ^a,b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b Department of Anesthesiology   (United States)

Author keywords

Lactate; Pathogenesis of sepsis; Protocolized care; Severe sepsis; Steroids; Surviving Sepsis Campaign

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; DROTRECOGIN; HYDROCORTISONE; LACTIC ACID; PATTERN RECOGNITION RECEPTOR; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; STEROID;

ANTIBIOTIC THERAPY; APOPTOSIS; BLOOD CLOTTING; CELL ACTIVATION; CELL CYCLE; CELL SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED PRACTICE; GOAL ATTAINMENT; HUMAN; INFLAMMATION; LONG TERM CARE; MICROORGANISM; MORBIDITY; MORTALITY; PATHOGENESIS; PATTERN RECOGNITION; PHENOTYPE; RESUSCITATION; REVIEW; SCREENING; SEPSIS; SEPTIC SHOCK; TISSUE PERFUSION; TREATMENT OUTCOME; VIRULENCE;

ANTI-BACTERIAL AGENTS; APOPTOSIS; DISEASE MANAGEMENT; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; PRACTICE GUIDELINES; PROTEIN C; SEPSIS; SHOCK, SEPTIC;

EID: 34347397197     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32818be70a     Document Type: Review

References (63)

1. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006; 6:813-822.
2. Patel NJ, Zaborina O, Wu L, et al. Recognition of intestinal epithelial HIF-1alpha activation by Pseudomonas aeruginosa. Am J Physiol Gastrointest Liver Physiol 2007; 292:G134-G142. This study describes the microbial virulence strategy in hypoxic conditions.
3. Creagh EM, O'Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006; 27:352-357.
4. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med 2007; 84:712-725.
5. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:446-458.
6. Granucci F, Foti M, Ricciardi-Castagnoli P. Dendritic cell biology. Adv Immunol 2005; 88:193-233.
7. Matejovic M, Krouzecky A, Rokyta R Jr, et al. Effects of combining inducible nitric oxide synthase inhibitor and radical scavenger during porcine bacteremia. Shock 2007; 27:61-68.
8. Cinel I, Buyukafsar K, Cinel L, et al. The role of poly(ADP-ribose) synthetase inhibition in preventing endotoxemia-induced intestinal epithelial apoptosis. Pharmacol Res 2002; 46:119-127.
9. Taner S, Cinel I, Ozer L, et al. Poly(ADP-ribose) synthetase inhibition reduces bacterial translocation in rats after endotoxin challenge. Shock 2001; 16:159-162.
10. Soriano FG, Nogueira AC, Caldini EG, et al. Potential role of poly(adenosine 5′-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock. Crit Care Med 2006; 34:1073-1079.
11. Doruk N, Buyukakilli B, Cinel I, et al. The effect of preventive use of alanylglutamine on diaphragm muscle function in cecal ligation and puncture-induced sepsis model. J Parenter Enteral Nutr 2005; 29:36-43.
12. Singleton KD, Wischmeyer PE. Glutamine's protection against sepsis and lung injury is dependent on heat shock protein 70 expression. Am J Physiol Regul Integr Comp Physiol 2007 [Epub ahead of print].
13. Dellinger RP. Inflammation and coagulation: implications for the septic patients. Clin Infect Dis 2003; 36:1259-1265.
14. Shorr AF, Bernard GR, Dhainaut JF, et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care 2006; 10:R92-R100.
15. Aupeix K, Hugel B, Martin T, et al. The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest 1997; 99:1546-1554.
16. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 2004; 9:1118-1135.
17. Azevedo LC, Janiszewski M, Soriano FG, Laurindo FR. Redox mechanisms of vascular cell dysfunction in sepsis. Endocr Metab Immune Disord Drug Targets 2006; 6:159-164.
18. Trzeciak S, Dellinger RP, Parrillo JE, et al., Microcirculatory Alterations in Resuscitation and Shock Investigators. Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemodynamics, oxygen transport, and survival. Ann Emerg Med 2007; 49:88-98. This was a study of the early microcirculatory perfusion derangements in patients with severe sepsis/septic shock and the microcirculation difference between survivors and nonsurvivors.
19. Fujimi S, Ogura H, Tanaka H, et al. Activated polymorphonuclear leukocytes enhance production of leukocyte microparticles with increased adhesion molecules in patients with sepsis. J Trauma 2002; 52:443-448.
20. Soriano AO, Jy W, Chirinos JA, et al. Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med 2005; 33:2540-2546.
21. Elbers PE, Ince C. Mechanisms of critical illness - classifying microcirculatory flow abnormalities in distributive shock. Crit Care 2006; 10:221-228.
22. Kreymann G, Grosser S, Buggisch P, et al. Oxygen consumption and resting metabolic rate in sepsis, sepsis syndrome, and septic shock. Crit Care Med 1993; 21:1012-1019.
23. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27:1230-1251.
24. Larche J, Lancel S, Hassoun SM, et al. Inhibition of mitochondrial permeability transition prevents sepsis-induced myocardial dysfunction and mortality. J Am Coll Cardiol 2006; 48:377-385. Recent publication showing the role of mitochondrial permeability transition in sepsis-induced organ dysfunction.
25. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360:219-223.
26. Chang KC, Unsinger J, Davis CG, et al. Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis. FASEB J 2007; 21:708-719.
27. Felmet KA, Hall MW, Clark RS, et al. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 2005; 174:3765-3772.
28. Toti P, De Felice C, Occhini R, et al. Spleen depletion in neonatal sepsis and chorioamnionitis. Am J Clin Pathol 2004; 122:765-771.
29. Hotchkiss RS, Osmon SB, Chang KC, et al. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005; 174:5110-5118.
30. Ozdulger A, Cinel I, Koksel O, et al. The protective effect of N-acetylcysteine on apoptotic lung injury in cecal ligation and puncture-induced sepsis model. Shock 2003; 19:366-372.
31. Le Tulzo Y, Pangault C, Gacouin A, et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002; 18:487-494.
32. Guisset O, Dilhuydy MS, Thiebaut R, et al. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med 2007; 33:148-152. This recent study demonstrates the importance of blood dendritic cell count for the assessment of the severity of the host response against infection in septic shock patients.
33. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873.
34. Cinel I, Dellinger RP. Current treatment of severe sepsis. Curr Infect Dis Rep 2006; 8:358-365. The authors recommended evidence-based protocolized care in the treatment of severe sepsis and septic shock.
35. Gladden LB. Lactate metabolism - a new paradigm for the third millennium. J Physiol 2004; 558:5-30.
36. +ATPase activity and raised lactate concentrations in septic shock: a prospective study. Lancet 2005; 365:871-875.
37. Revelly JP, Tappy L, Martinez A, et al. Lactate and glucose metabolism in severe sepsis and septic shock. Crit Care Med 2005; 33:2235-2240.
38. Mackenzie I, Woodhouse J. C-reactive protein concentrations during bacteraemia: A comparison between patients with and without liver dysfunction. Intensive Care Med 2006; 32:1344-1351.
39. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34:1996-2003. A meta-analysis of 32 published studies, summarizing the current knowledge on procalcitonin as a biological diagnostic marker for sepsis, severe sepsis or septic shock.
40. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-607.
41. Luyt CE, Guerin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171:48-53.
42. Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identi-fication of critically ill patients at high risk of mortality. Crit Care Med 2006; 34:2596-2602.
43. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension prior to initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596. This is an investigation showing the importance of early intravenous antibiotic therapy in sepsis.
44. Damas P, Canivet JL, Ledoux D, et al. Selection of resistance during sequential use of preferential antibiotic classes. Intensive Care Med 2006; 32:67-74.
45. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl JMed 2001; 345:1368-1377.
46. Vincent JL, Sakr Y, Reinhart K, et al., 'Sepsis Occurrence in Acutely Ill Patients' Investigators. Is albumin administration in the acutely ill associated with increased mortality? Results of the SOAP study. Crit Care 2005; 9:R745-R754.
47. Harvey S, Harrison DA, Singer M, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 2005; 366:472-477.
48. Wheeler AP, Bernard GR, Thompson BT, et al. Pulmonary artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213-2224.
49. Varpula M, Tallgren M, Saukkonen K, et al. Hemodynamic variables related to outcome in septic shock. Intensive Care Med 2005; 31:1066-1071.
50. Reinhart K, Kuhn HJ, Hartog C, Bredle DL. Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill. Intensive Care Med 2004; 30:1572-1578.
51. Ladakis C, Myrianthefs P, Karabinis A, et al. Central venous and mixed venous oxygen saturation in critically ill patients. Respiration 2001; 68:279-285.
52. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247-2256.
53. Sprung CL, Annane D, Briegel J, et al. Corticosteroid therapy of septic shock (CORTICUS) [abstract B97]. Am J Respir Crit Care Med 2007; 175:A507.
54. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. J Am Med Assoc 2002; 288:862-871.
55. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: efficacy and safety of recombinant human activated protein Cfor severe sepsis. N Engl J Med 2001; 344:699-709.
56. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341.
57. Dellinger RP. Recombinant activated protein C: decisions for administration. Crit Care Med 2006; 34:530-531.
58. Eichacker PQ, Natanson C. Increadsing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 2007; 33:396-399.
59. Bae JS, Yang L, Manithody C, Rezaie AR. Engineering a disulfide bond to stabilize the calcium binding loop of activated protein C eliminates its anticoagulant but not protective signaling properties. J Biol Chem 2007; 282:9251-9259. Recent study which provides activated protein C mutant as an important tool for in-vivo studies to examine the role of anticoagulant versus anti-inflammatory function of activated protein C.
60. Cinel I, Dellinger RP. Guidelines for severe infections: Are they useful? Curr Opin Crit Care Med 2006; 12:483-488.
61. Levy MM, Pronovost PJ, Dellinger RP, et al. Sepsis change bundles: Converting guidelines into meaningful change in behavior and clinical outcome. Crit Care Med 2004; 32:S595-S597.
62. Gao F. Will sepsis care bundles improve patient outcome? Adv Sepsis 2006; 5:94-96.
63. Schorr C, Trzeciak S, Fakorede F, et al. Surviving Sepsis Campaign (SSC) performance improvement program: demonstration of process change [abstract]. Crit Care Med 2006; 34 (Suppl.):A107.